2023年3月3日

全球胰島素泵市場規模預計將以8.46%的複合年增長率增長2022 - 2028市場驅動和機會技術進步徹底改變了胰島素輸送胰島素泵市場不斷發展的新功能與技術進步就像智能胰島素泵的啟動和連接設備。大多數行業參與者,比如美敦力公司,串聯糖尿病護理,Insulet公司,和其他技術的不斷發展進步和近年來新產品交付。爆炸在研發和出版研究閉環係統與胰島素泵在糖尿病管理提供了新的胰島素泵市場增長機會。一些混合動力係統預計將在未來商業化與胰島素交付。除了那些已經在市場上,各種係統將啟動。例如,DBLG1 (Diabeloop,法國格勒諾布爾)獲得了CE市場在歐洲國家在1型糖尿病中的應用成人患者人群。產品如insulin-only iLEt(β仿生學,美國)和Omnipod地平線(Insulet Billerica,美國)在臨床試驗和預計到達該行業在未來。增加糖尿病患病率和支出在整個糖尿病人群中,1型糖尿病患者高度依賴胰島素的外部支持交付。這些主要患者群體極大地推動胰島素泵市場的增長。2021年,糖尿病患病率估計20 - 79歲的成年人中增加了三倍多,從1.51億年估計(大約4.6%的全球人口的2000)到2021年的大約5.37億名(10.5%)。 Based on that, by 2030, around 643 million population expected to increase. And if the prevalence rate remains the same, it is expected to jump to around 783 million (12.2%) by 2045. Government Initiatives for Diabetes Care Management Rising government initiatives for diabetes care management highly drive insulin pump market growth. Responding to the increasing burden of diabetes worldwide delivers a high demand for care. It positively influenced government initiatives and funding from public and private entities to improve global, regional, and national diabetes health improvements. Based on that, several government and health authorities are making efforts for diabetes care access to comprehensive, equitable, affordable, quality care and medical and technology-based treatments. Available Reimbursement Policies and Healthcare Insurance for Insulin Pump The cost of an insulin pump and associated insulin solutions is comparatively higher than other insulin delivery solutions due to the advancement and additional features associated with the products. However, the available reimbursement policies and healthcare insurance coverage highly support the adoption of insulin pumps. In most countries, these policies favor patients who reduce the cost burden and accelerate the adoption of insulin pumps. These insurances cover the insulin pump and include the insulin pump consumables. This is one of the positive signs that is driving the insulin pump market at a faster rate. Vendor Landscape The global insulin pump market is highly concentrated, with a limited number of players. Various innovative products like patch pumps are being introduced into the market, and the adoption rate is comparatively higher. Tandem Diabetes Care is one of the leading companies in the insulin pump market; estimated that around 750,000 people in the U.S. are currently using an insulin pump. Moreover, the company stated that approximately 450,000 people use insulin pumps in more than 20 countries outside the United States. The company's insulin pump is widely available in the global market. Key Company Profiles